AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Crinetics Pharmaceuticals, Inc. Director's Dealing 2025

Jan 29, 2025

31156_dirs_2025-01-29_57b2be26-37b0-409d-a864-5d7c07a9e9cc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2024-12-31

Reporting Person: Betz Stephen F. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-20	Common Stock	J	451	$14.98	Acquired	71358	Direct

Footnotes

F1: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),